As more companies explore live biotherapeutic products, ensuring stability is likely to be front and center with unique challenges for oral and topical applications.
- We Must Rethink The Solvents We Use For Peptide Synthesis
- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
- Why You Need A Raw Material Control Strategy
- Why Pharma Risk Assessments Should Include 'Working Together Alone'
- Climbing The Blockchain Ladder To Optimize Clinical Supply Forecasting
- How CAR-NKs Offer Powerful Therapeutic Flexibility
- Ramping Up GMP-Compliant CAR-NK Manufacturing At Scale With iPSCs
EDITOR'S DESK
-
2025 Cell Therapy Outlook From BPI West
Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.
Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.
Editor Tyler Menichiello reviews the most compelling topics and sessions from this year's BioProcess International U.S. West.
Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.
Gilead's chief sustainability officer and SVP of operations, Joydeep Ganguly, explains the company's cultural focus on sustainability and how it influences everything from R&D to manufacturing.
GUEST COLUMNISTS
-
We Must Rethink The Solvents We Use For Peptide Synthesis
While the effectiveness of GLP-1 in weight loss is good news, the use of organic solvents in the GLP-1 synthesis and purification process is a growing pain that needs to be addressed.
-
Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
The U.S. tariffs on trading partners bring a whole new set of challenges, but there are tactics and strategies companies can deploy to help offset the cost and operational impacts.
-
Why You Need A Raw Material Control Strategy
You should start with the end goal in mind, but the first draft is almost never the last. These living documents should evolve as your team gains process knowledge.
-
Why Pharma Risk Assessments Should Include 'Working Together Alone'
When understood and managed properly, subjectivity becomes a source of creativity. It reveals hidden hazards and unlocks more effective risk controls.
-
Climbing The Blockchain Ladder To Optimize Clinical Supply Forecasting
Layering AI on top of blockchain technology offers a powerful way to predict kinks in the supply chain. Here's a look at where the technology is headed.
-
How CAR-NKs Offer Powerful Therapeutic Flexibility
Induced pluripotent stem cells have emerged as a promising platform for producing CAR-engineered NK cells in a standardized, renewable, and scalable way.
-
Ramping Up GMP-Compliant CAR-NK Manufacturing At Scale With iPSCs
The ability to produce billions of NK cells in a single production run represents a transformative shift in the economics and logistics of cell therapy.
-
Pharmaceutical Sovereignty: The Resilience We Cannot Outsource
Pharmaceutical sovereignty is no longer a theoretical concern. Sovereignty in this context does not imply isolation, but rather strategic resilience: building robust national and regional capabilities that ensure security while enabling global collaboration.
BIOPROCESSING WHITE PAPERS
-
Extractables And Leachables Testing
Learn how to navigate the extractables and leachables regulatory landscape and implement best practices for leachables analysis in your pharmaceutical development process.
-
Navigating Your Digital Journey To AI Success11/2/2023
The first critical step in your digital journey, before implementing AI, is to ensure you’re at the right level of digital maturity.
-
From CLD To CDMO: Demonstrating A Successful Cell Line Technology Transfer8/5/2024
Explore critical considerations for biopharmaceutical developers and CDMOs during technology transfer as well as a successful transfer and scale-up of a cell line from a CLD platform to a global CDMO.
-
The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics5/16/2024
Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.
-
Exploring Perfusion Technology For Virus Manufacturing Process Intensification1/28/2025
Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.
-
Bioconjugates – An Increasing Diversity, A Blossoming Of Therapeutic Applications10/24/2024
Harness the power of bioconjugation to revolutionize targeted therapies, enhance drug efficacy, and reduce side effects, paving the way for more precise and effective treatments across a range of diseases.
BIOPROCESSING APP NOTES & CASE STUDIES
- Advantages Of Spray-Dried Mannitol In Roll Compaction
- Overcoming The Solubility Challenges Of Antibody-Drug Conjugates
- Developing A HIC Polishing Step For The Removal Of mAb Aggregates
- Rapid Walkaway Solution For Assessing Viability In Cancer Organoids
- Molecular Weight Confirmation For Length, Integrity And Impurity Analysis Of A 70-Mer Oligonucleotide
BIOPROCESS ONLINE CONTENT COLLECTIONS

This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 04.23.25 -- Accelerating Bioprocessing: Smarter DSP, Analytics, And Scale-Up
- 04.23.25 -- Impressions And Takeaways From BPI West 2025
- 04.22.25 -- Business of Biotech Newsletter
- 04.22.25 -- Enhancing Precision & Efficiency In Gene Editing Research
- 04.22.25 -- March 2025 — CDMO Opportunities And Threats Report